INTI fundamentals

Key facts

—

—

—

—

—

—

—

—

About

Inhibitor Therapeutics, Inc. engages in the discovery, development, and commercialization of therapeutics for patients with cancer. It focuses on SUBA-Itraconazole, a patented, oral formulation of Itraconazole, for treatment of prostate and lung cancers. The company was founded on September 30, 1992 and is headquartered in Tampa, FL.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

INTI has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company